Investigation of the causal relationship between ALS and autoimmune disorders: a Mendelian randomization study

Table 2 Results of the MR analyses between liability to autoimmune disorders and the ALS risk

Exposure	N SNPs	r²	F-statistics	Inverse variance weighted			Weighted median			MR Egger
Exposure	N SNPs	r²	F-statistics	OR	CI	pval	OR	CI	pval	OR	CI	pval
Asthma	67	0.002	71.785	1.014	0.964–1.066	0.599	1.031	0.955–1.113	0.437	0.988	0.862–1.132	0.859
CD	76	0.010	96.324	0.984	0.963–1.005	0.124	1.005	0.977–1.033	0.750	1.053	0.997–1.113	0.067
CeD	15	0.057	333.990	1.016	0.992–1.040	0.185	1.019	0.995–1.044	0.122	1.007	0.972–1.044	0.701
IBS	5	0.001	38.970	1.013	0.727–1.412	0.940	0.960	0.667–1.384	0.825	0.047	0.002–1.403	0.176
MS	68	0.009	69.687	0.985	0.962–1.008	0.166	0.974	0.943–1.007	0.666	1.027	0.977–1.080	0.750
PBC	40	0.018	92.080	1.007	0.984–1.031	0.547	1.024	0.995–1.055	0.104	1.009	0.943–1.080	0.795
PSC	12	0.021	42.303	0.978	0.934–1.024	0.349	0.990	0.944–1.38	0.677	1.169	0.940–1.454	0.192
PsO	53	0.310	58.132	1.005	1.001–1.009	0.012	1.003	0.997–1.009	0.312	1.004	0.999–1.009	0.132
RA	51	0.010	64.953	0.976	0.945–1.008	0.833	0.971	0.928–1.015	0.976	0.946	0.898–0.997	0.373
T1D	32	0.021	71.107	0.998	0.978–1.018	0.830	0.984	0.955–1.015	0.312	1.026	0.986–1.067	0.219
UC	54	0.008	72.544	1.002	0.975–1.028	0.911	0.987	0.954–1.022	0.481	1.021	0.938–1.110	0.637
SLE	39	0.034	117.386	0.995	0.980–1.010	0.509	0.996	0.977–1.016	0.694	0.981	0.950–1.014	0.269

The ORs express effects of liability to each exposure on ALS risk
OR odds ratio, CI confidence interval, MR Mendelian randomization, SNP single nucleotide polymorphism, r² proportion of variance in exposure variable explained by SNPs, F-statistics “strength” of the instrumental variable, CD Crohn’s disease, CeD celiac disease, IBS irritable bowel syndrome, MS multiple sclerosis, PBC primary biliary cirrhosis, PSC primary sclerosing cholangitis, PsO psoriasis, RA rheumatoid arthritis, T1D type 1 diabetes, UC ulcerative colitis, SLE systemic lupus erythematosus

ISSN: 1741-7015